Hospitals filled to capacity. Case counts climbing by the hour. Quarantine became routine. It was the beginning of the ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...

Earlier in April 2026, BioNTech reported positive primary Phase 2 results for its HER2‑targeted antibody-drug conjugate trastuzumab pamirtecan in previously treated, advanced endometrial cancer, ...

BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.

The drug candidate, Trastuzumab Pamirtecan, also holds both FDA Fast Track and Breakthrough Therapy designations. Phase 3 trials are underway, and a Biologics License Application is planned for 2026.

The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to ...

By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to ‌start again with a new ...